Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Income from Continuing Operations (2023 - 2025)

Immunome's Income from Continuing Operations history spans 3 years, with the latest figure at 72861000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 12.18% year-over-year to 72861000.0; the TTM value through Dec 2025 reached 224113000.0, up 26.71%, while the annual FY2025 figure was 224113000.0, 26.71% up from the prior year.
  • Income from Continuing Operations reached 72861000.0 in Q4 2025 per IMNM's latest filing, down from 60138000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 4471000.0 in Q1 2023 to a low of 132299000.0 in Q1 2024.
  • Average Income from Continuing Operations over 3 years is 53286916.67, with a median of 48500000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: crashed 2859.05% in 2024, then skyrocketed 66.26% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 94653000.0 in 2023, then grew by 12.34% to 82970000.0 in 2024, then grew by 12.18% to 72861000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Income from Continuing Operations are 72861000.0 (Q4 2025), 60138000.0 (Q3 2025), and 46478000.0 (Q2 2025).